Clinical trials and recent meta-analyses consistently show tirzepatide delivers the most substantial weight reduction among GLP-1 medications, with average losses of up to 22.5% of body weight
For example, Kaiser Permanente Northwest Region covers Wegovy as a prescription drug benefit if patients meet the following criteria: Have been diagnosed with chronic weight management Are 18 years or older Have documented their current weight and body mass index (BMI) Are actively following a diet and exercise program Have a BMI of 30 or higher or have a BMI of 27 or higher, plus hypertension, diabetes, or hyperlipidemia Failed a three-month trial or has an allergy, intolerance, or contraindication to phentermine, diethylpropion, Qsymia, and Contrave Failed a three-month trial of Ozempic Medicare doesnt cover medications strictly for weight loss, so Kaiser Medicare Part D plans typically wont cover Wegovy for weight loss alone
A meta-analysis showed that women with PCOS have a lower overall diet quality with higher cholesterol, lower magnesium and lower zinc intake
Red flags include persistent vomiting, severe abdominal bloating or pain, constipation lasting several days without relief, or unintended and significant weight loss
Learn how your comment data is processed